YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Bioh…
Ono Pharmaceutical Co. (OPHLF) shares ended the last trading session 13.9% higher at $16.11. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.8…
Companies to create novel antibody therapeutics to treat fibrosis across a broad range of indications Ono to leverage Mediar's expertise in antibody discovery and harness its deep understanding of myofibroblast biology to develop a new cla…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Ono Pharmaceutical (TSE:4528) has drawn fresh attention after repor…
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at val…
Ono Pharmaceutical Co. (OPHLF) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurri…
Ionis Pharmaceuticals IONS reported second-quarter 2026 adjusted loss per share of 43 cents, narrower than the Zacks Consensus Estimate of a loss of 89 cents. In the year-ago period, the company had posted adjusted earnings of 86 cents. Th…
Wall Street expects a year-over-year increase in earnings on higher revenues when Bioventus (BVS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings pic…
OSAKA, Japan and SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (TYO: 4528, "Ono") and Phylo, Inc. ("Phylo") today announced a collaboration that brings Biomni Lab, Phylo's agentic AI platform for b…
Wall Street expects a year-over-year decline in earnings on lower revenues when Ono Pharmaceutical Co. (OPHLF) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's…
Ono Pharmaceutical Co. (OPHLF) shares rallied 9.2% in the last trading session to close at $14.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
[Moscow, Russia - April 7, 2019: NVIDIA video chip on the motherboard] Antonio Bordunovi/iStock Editorial via Getty Images Nvidia (NVDA [https://seekingalpha.com/symbol/NVDA]) on Wednesday unveiled a broad slate of AI products, partnership…
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly l…
Ono Pharmaceutical Co. (OPHLF) shares ended the last trading session 10.4% higher at $14.9. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.2%…
Global pivotal Phase 3 study will evaluate the efficacy and safety over a 52-week treatment period Polycythemia Vera (PV) is a rare and potentially life-threatening hematologic disease with significant persistent unmet need Sapablursen rec…
Company Logo Key market opportunities in thyroid cancer therapeutics include China's anticipated rise in cases through 2029, the growing importance of targeted therapies and emerging immunotherapies, a robust pipeline with 119 molecules in…
DelveInsight Business Research LLP The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis Ph…
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires. As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 analy…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Ono Pharmaceutical (TSE:4528) is back in focus after expanding its collaboration with Congruence…
SAN DIEGO, March 03, 2026--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced a target disc…
Expanded collaboration continues to leverage Congruence's proprietary computationaldrug discovery engine, Revenir™ to deliver Development Candidates in Neurology and Immunology Congruence to receive undisclosed upfront payment as well as R…
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on February 25, reporting that total reven…
* Ono Pharmaceutical press release [https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/2026_3r_en%7D.pdf] (OPHLF [https://seekingalpha.com/symbol/OPHLF]): for the nine-month ended it reported GAAP EPS of ¥146.07…
OSAKA, Japan, January 15, 2026--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (TSE:4528), today announced that Toichi Takino, President and COO, presented at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026,…
OSAKA, Japan, January 12, 2026--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (TSE:4528) today announced that Toichi Takino, President and COO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 202…
Scenic Biotech Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Sc…
If you have been wondering whether Ono Pharmaceutical is still a smart buy at today’s price, you are not alone, and this article is going to unpack what the current share price really implies about future returns. The stock has climbed 27.…
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development o…
Company Logo The global portal hypertension drugs market is thriving due to rising liver disease rates, particularly cirrhosis and hepatitis, and an aging global population, leading to heightened demand for effective therapies. Key players…
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milesto…
Harness Therapeutics Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment Proprietary MISBA Duo technology is the first platform to enable simultaneous, controlled upregulation…
If you have been eyeing Ono Pharmaceutical and wondering whether now is the right time to jump in, you are not alone. Lots of investors are debating what to do next with this stock, especially given the mix of intriguing signals from both…
Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union OSAKA, Japan & WALTHAM, Mass., July 28, 2025--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical compa…
[Businessmen making handshake with partner, greeting, dealing, merger and acquisition, business cooperation concept, for business, finance and investment background, teamwork and successful business] Tippapatt Vertex Pharmaceuticals (Nasda…
- Exclusive collaboration and license agreement for povetacicept in these countries - - Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate ad…
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement i…